{"organizations": [], "uuid": "1c5b797d32e2ea24aadc446d65bd4fda0481c32b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180522.html", "section_title": "Archive News &amp; Video for Tuesday, 22 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-pavmed-q1-adjusted-non-gaap-loss-p/brief-pavmed-q1-adjusted-non-gaap-loss-per-share-0-10-idUSASC0A36X", "country": "US", "domain_rank": 408, "title": "BRIEF-PAVmed Q1 Adjusted Non-GAAP Loss Per Share $0.10", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-22T19:39:00.000+03:00", "replies_count": 0, "uuid": "1c5b797d32e2ea24aadc446d65bd4fda0481c32b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-pavmed-q1-adjusted-non-gaap-loss-p/brief-pavmed-q1-adjusted-non-gaap-loss-per-share-0-10-idUSASC0A36X", "ord_in_thread": 0, "title": "BRIEF-PAVmed Q1 Adjusted Non-GAAP Loss Per Share $0.10", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eu", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 22 (Reuters) - PAVmed Inc:\n* PAVMED REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS * Q1 ADJUSTED NON-GAAP LOSS PER SHARE $0.10\n* Q1 GAAP LOSS PER SHARE $0.21 * REMAIN ON TARGET TO FILE RESUBMISSION RELATED TO CARPX TO U.S. FDA BY END OF MAY\n* PAVMED - IDENTIFIED EU NOTIFIED BODY, TAKING ADDITIONAL REQUISITE STEPS TO SUBMIT APPLICATION FOR CE MARK FOR CARPX IN EUROPE, TARGETED FOR LATE Q3\n* ALSO TOOK STEPS TO INITIATE A RIGHTS OFFERING WHICH CO EXPECTS TO LAUNCH THIS WEEK\n* COMMON STOCK HOLDERS WILL BE GRANTED ONE RIGHT TO PURCHASE A NEW UNIT CONSISTING OF A SHARE OF STOCK AND A SERIES Z WARRANT FOR $2.25 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-22T19:39:00.000+03:00", "crawled": "2018-05-23T15:27:44.105+03:00", "highlightTitle": ""}